Carolyn Beckby Dan Stanton
Fully closed and automated platforms are key to reducing the current high costs of cell and gene therapy manufacturing, say industry experts.
Cell and gene therapies (CGTs) have come a long way over the past two years, …
by Dan Stanton
This is the first time in history that we can make more effective medicines than we can afford, says Dark Horse Consulting.
The Phacilitate conference took place in Miami this week, and in the plenary session Anthony …
Campbell, CA, January 21st, 2019 – Dark Horse Consulting, the leading consultancy specializing in cell and gene therapy product development, today announced its planned attendance and sponsorship of the 2019 Phacilitate Leaders World meeting, scheduled for January 22-25 in Miami, …
by Dan Stanton
The US FDA predicts it will receive more than 200 regenerative INDs per year from 2020 and will add 50 additional staff to review these products.
There has been “a large upswing in the number of investigational …
by Katy Spink & Andrew Steinsapir
With the 2017 FDA approvals and launches of the first gene-modified cell and pure-play gene therapy products to gain licensure in the United States, increasing attention has been paid to the high cost of …
